| ［1］ |
中国康复医学会皮肤病康复专业委员会, 中华医学会皮肤性病学分会光动力治疗研究中心, 中国医学装备协会皮肤病与皮肤美容分会光医学治疗装备学组. 中国光线性角化病临床诊疗专家共识（2021）［J］. 中华皮肤科杂志, 2021,54（12）:1048⁃1056. doi: 10.35541/cjd.20210561.
|
| ［2］ |
Flohil SC, van der Leest RJ, Dowlatshahi EA, et al. Prevalence of actinic keratosis and its risk factors in the general population: the Rotterdam study［J］. J Invest Dermatol, 2013,133（8）:1971⁃1978. doi: 10.1038/jid.2013.134.
|
| ［3］ |
Fargnoli MC, Altomare G, Benati E, et al. Prevalence and risk factors of actinic keratosis in patients attending Italian dermatology clinics［J］. Eur J Dermatol, 2017,27（6）:599⁃608. doi: 10.1684/ejd.2017.3126.
|
| ［4］ |
Xu D, Sun JF, Qi RQ, et al. A multicenter retrospective analysis of the clinical and pathological characteristics of 1 188 cases of actinic keratosis in different ultraviolet radiation intensity areas of China［J］. J Cosmet Dermatol, 2022,21（7）:2879⁃2888. doi: 10.1111/jocd.14479.
|
| ［5］ |
Ratushny V, Gober MD, Hick R, et al. From keratinocyte to cancer: the pathogenesis and modeling of cutaneous squamous cell carcinoma［J］. J Clin Invest, 2012,122（2）:464⁃472. doi: 10.1172/JCI57415.
|
| ［6］ |
Criscione VD, Weinstock MA, Naylor MF, et al. Actinic keratoses: natural history and risk of malignant transformation in the Veterans affairs topical tretinoin chemoprevention trial［J］. Cancer, 2009,115（11）:2523⁃2530. doi: 10.1002/cncr.24284.
|
| ［7］ |
Fernandez Figueras MT. From actinic keratosis to squamous cell carcinoma: pathophysiology revisited［J］. J Eur Acad Dermatol Venereol, 2017,31 Suppl 2:5⁃7. doi: 10.1111/jdv.14151.
|
| ［8］ |
Xu G, Fang J, Xu J, et al. Expression and significance of mammalian target of rapamycin in cutaneous squamous cell carcinoma and precancerous lesions［J］. Bioengineered, 2021,12（2）:9930⁃9938. doi: 10.1080/21655979.2021.1984719.
|
| ［9］ |
Weber P, Sinz C, Rinner C, et al. Perilesional sun damage as a diagnostic clue for pigmented actinic keratosis and Bowen′s disease［J］. J Eur Acad Dermatol Venereol, 2021,35（10）:2022⁃2026. doi: 10.1111/jdv.17464.
|
| ［10］ |
Rongioletti F. Actinic keratoses: what classification is useful to predict the risk of progression? Pros and cons［J］. J Eur Acad Dermatol Venereol, 2019,33（6）:983⁃984. doi: 10.1111/jdv.15649.
|
| ［11］ |
Papageorgiou C, Lallas A, Manoli SM, et al. Evaluation of dermatoscopic criteria for early detection of squamous cell carcinoma arising on an actinic keratosis［J］. J Am Acad Dermatol, 2022,86（4）:791⁃796. doi: 10.1016/j.jaad.2021.03.111.
|
| ［12］ |
Peppelman M, Nguyen KP, Hoogedoorn L, et al. Reflectance confocal microscopy: non⁃invasive distinction between actinic keratosis and squamous cell carcinoma［J］. J Eur Acad Dermatol Venereol, 2015,29（7）:1302⁃1309. doi: 10.1111/jdv.12806.
|
| ［13］ |
Zhu AQ, Wang LF, Li XL, et al. High⁃frequency ultrasound in the diagnosis of the spectrum of cutaneous squamous cell carcinoma: noninvasively distinguishing actinic keratosis, Bowen′s disease, and invasive squamous cell carcinoma［J］. Skin Res Technol, 2021,27（5）:831⁃840. doi: 10.1111/srt.13028.
|
| ［14］ |
Sanchez⁃Vega F, Mina M, Armenia J, et al. Oncogenic signaling pathways in the cancer genome atlas［J］. Cell, 2018,173（2）:321⁃337.e10. doi: 10.1016/j.cell.2018.03.035.
|
| ［15］ |
He S, Sharpless NE. Senescence in health and disease［J］. Cell, 2017,169（6）:1000⁃1011. doi: 10.1016/j.cell.2017.05.015.
|
| ［16］ |
Hodges A, Smoller BR. Immunohistochemical comparison of p16 expression in actinic keratoses and squamous cell carcinomas of the skin［J］. Mod Pathol, 2002,15（11）:1121⁃1125. doi: 10.1097/01.MP.0000032536.48264.D1.
|
| ［17］ |
牛蕊仙, 徐丹, 何黎. 光线性角化病向鳞状细胞癌转化的分子机制研究进展［J］. 中华皮肤科杂志, 2016,49（2）:144⁃146. doi:10.3760/cma.j.issn.0412⁃4030.2016.02.021.
|
| ［18］ |
Salama ME, Mahmood MN, Qureshi HS, et al. p16INK4a expression in actinic keratosis and Bowen′s disease［J］. Br J Dermatol, 2003,149（5）:1006⁃1012. doi: 10.1111/j.1365⁃2133. 2003.05654.x.
|
| ［19］ |
Bagazgoitia L, Cuevas J, Juarranz A. Expression of p53 and p16 in actinic keratosis, bowenoid actinic keratosis and Bowen′s disease［J］. J Eur Acad Dermatol Venereol, 2010,24（2）:228⁃230. doi: 10.1111/j.1468⁃3083.2009.03337.x.
|
| ［20］ |
Azazmeh N, Assouline B, Winter E, et al. Chronic expression of p16INK4a in the epidermis induces Wnt⁃mediated hyperplasia and promotes tumor initiation［J］. Nat Commun, 2020,11（1）:2711. doi: 10.1038/s41467⁃020⁃16475⁃3.
|
| ［21］ |
Harvey NT, Leecy T, Wood BA. Immunohistochemical staining for p16 is a useful adjunctive test in the diagnosis of Bowen′s disease［J］. Pathology, 2013,45（4）:402⁃407. doi: 10.1097/PAT. 0b013e328360c064.
|
| ［22］ |
Genders RE, Beck S, Bouwes Bavinck JN, et al. p16 immunostaining in keratinocytic neoplasia in organ transplant recipients: Bowen′s disease shows a characteristic pattern［J］. J Cutan Pathol, 2017,44（1）:28⁃33. doi: 10.1111/cup.12840.
|
| ［23］ |
Nasiri S, Azhari V, Bidari⁃Zerehpoosh F, et al. The diagnostic value of p63, p16, and p53 immunohistochemistry in distingui⁃shing seborrheic keratosis, actinic keratosis, and Bowen′s disease ［J］. Dermatol Ther, 2021,34（2）:e14817. doi: 10.1111/dth.14817.
|
| ［24］ |
Matsushima N, Miyashita H, Kretsinger RH. Sequence features, structure, ligand interaction, and diseases in small leucine rich repeat proteoglycans［J］. J Cell Commun Signal, 2021,15（4）:519⁃531. doi: 10.1007/s12079⁃021⁃00616⁃4.
|
| ［25］ |
Giatagana EM, Berdiaki A, Tsatsakis A, et al. Lumican in carcinogenesis⁃revisited［J］. Biomolecules, 2021,11（9）:1319. doi: 10.3390/biom11091319.
|
| ［26］ |
Takayama R, Ishiwata T, Ansai S, et al. Lumican as a novel marker for differential diagnosis of Bowen disease and actinic keratosis［J］. Am J Dermatopathol, 2013,35（8）:827⁃832. doi: 10.1097/DAD.0b013e31827c7f31.
|
| ［27］ |
Wu J, Liu T, Rios Z, et al. Heat shock proteins and cancer［J］. Trends Pharmacol Sci, 2017,38（3）:226⁃256. doi: 10.1016/j.tips. 2016.11.009.
|
| ［28］ |
Rosenzweig R, Nillegoda NB, Mayer MP, et al. The Hsp70 chaperone network［J］. Nat Rev Mol Cell Biol, 2019,20（11）:665⁃680. doi: 10.1038/s41580⁃019⁃0133⁃3.
|
| ［29］ |
Sherman MY, Gabai VL. Hsp70 in cancer: back to the future［J］. Oncogene, 2015,34（32）:4153⁃4161. doi: 10.1038/onc.2014.349.
|
| ［30］ |
樊欣, 彭仁. 热休克蛋白70: 生物学功能与作用机制研究进展［J］. 生命科学, 2019,31（3）:270⁃278. doi: 10.13376/j.cbls/2019 039.
|
| ［31］ |
Fernández⁃Guarino M, Zamorano León JJ, López Farré AJ, et al. Cytoplasmic increase in Hsp70 protein: a potential new biomarker of early infiltration of cutaneous squamous cell carcinoma arising from actinic keratosis［J］. Cancers（Basel）, 2020,12（5）:1151. doi: 10.3390/cancers12051151.
|
| ［32］ |
Neto PD, Alchorne M, Michalany N, et al. Reduced p53 staining in actinic keratosis is associated with squamous cell carcinoma: a preliminary study［J］. Indian J Dermatol, 2013,58（4）:325. doi: 10.4103/0019⁃5154.113935.
|
| ［33］ |
Nindl I, Gottschling M, Krawtchenko N, et al. Low prevalence of p53, p16（INK4a） and Ha⁃ras tumour⁃specific mutations in low⁃graded actinic keratosis［J］. Br J Dermatol, 2007,156（Suppl 3）:34⁃39. doi: 10.1111/j.1365⁃2133.2007.07857.x.
|
| ［34］ |
Bakshi A, Shafi R, Nelson J, et al. The clinical course of actinic keratosis correlates with underlying molecular mechanisms［J］. Br J Dermatol, 2020,182（4）:995⁃1002. doi: 10.1111/bjd.18338.
|
| ［35］ |
Heerfordt IM, Nissen CV, Poulsen T, et al. Thickness of actinic keratosis does not predict dysplasia severity or p53 expression［J］. Sci Rep, 2016,6:33952. doi: 10.1038/srep33952.
|
| ［36］ |
Osanai M, Takasawa A, Murata M, et al. Claudins in cancer: bench to bedside［J］. Pflugers Arch, 2017,469（1）:55⁃67. doi: 10.1007/s00424⁃016⁃1877⁃7.
|
| ［37］ |
Bhat AA, Syed N, Therachiyil L, et al. Claudin⁃1, a double⁃edged sword in cancer［J］. Int J Mol Sci, 2020,21（2）:569. doi: 10.3390/ijms21020569.
|
| ［38］ |
Hintsala HR, Siponen M, Haapasaari KM, et al. Claudins 1, 2, 3, 4, 5 and 7 in solar keratosis and squamocellular carcinoma of the skin［J］. Int J Clin Exp Pathol, 2013,6（12）:2855⁃2863.
|
| ［39］ |
Lee JS, Park HS, Yoon HS, et al. Claudin⁃1 expression decreases with increasing pathological grade in actinic keratosis and may be a marker of high⁃risk actinic keratosis［J］. Clin Exp Dermatol, 2019,44（5）:483⁃490. doi: 10.1111/ced.13810.
|
| ［40］ |
徐丹, 刘彤云, 袁瑞红, 等. 紫外线对光化性角化病和正常皮肤p53、基质金属蛋白酶2、9表达的影响［J］. 中华皮肤科杂志, 2013,46（2）:113⁃116. doi: 10.3760/cma.j.issn.0412⁃4030. 2013.02.012.
|
| ［41］ |
Wang H, Li H, Yan Q, et al. Serum matrix metalloproteinase⁃13 as a diagnostic biomarker for cutaneous squamous cell carcinoma［J］. BMC Cancer, 2021,21（1）:816. doi: 10.1186/s12885⁃021⁃08566⁃1.
|
| ［42］ |
张子玲, 张亚楠, 张艳丽, 等. EZH2的表观遗传调控在肿瘤发生中的研究进展［J］. 国际遗传学杂志, 2022,45（1）:44⁃49. doi:10.3760/cma.j.cn231536⁃20210810⁃00102.
|
| ［43］ |
Xie Q, Wang H, Heilman ER, et al. Increased expression of enhancer of Zeste Homolog 2（EZH2） differentiates squamous cell carcinoma from normal skin and actinic keratosis［J］. Eur J Dermatol, 2014,24（1）:41⁃45. doi: 10.1684/ejd.2013.2219.
|
| ［44］ |
Persechino F, Ranieri D, Guttieri L, et al. Expression profile of fibroblast growth factor receptors, keratinocyte differentiation markers, and epithelial mesenchymal transition⁃related genes in actinic keratosis: a possible predictive factor for malignant progression?［J］. Biology（Basel）, 2021,10（4）:331. doi: 10. 3390/biology10040331.
|
| ［45］ |
Bacchetti T, Ferretti G, Sahebkar A. The role of paraoxonase in cancer［J］. Semin Cancer Biol, 2019,56:72⁃86. doi: 10.1016/j.semcancer.2017.11.013.
|
| ［46］ |
Sartini D, Campagna R, Lucarini G, et al. Differential immunohistochemical expression of paraoxonase⁃2 in actinic keratosis and squamous cell carcinoma［J］. Hum Cell, 2021,34（6）:1929⁃1931. doi: 10.1007/s13577⁃021⁃00581⁃5.
|
| ［47］ |
Buechner SA, Resink TJ. T⁃cadherin expression in actinic keratosis transforming to invasive squamous cell carcinoma［J］. Dermatopathology（Basel）, 2019,6（1）:12⁃19. doi: 10.1159/000 495609.
|
